论文部分内容阅读
目的 探讨放化疗同时治疗食管癌的价值。方法 将 6 8例食管癌患者随机分为 2组 ,一组 35例放疗同时合并 5 Fu、PDD方案化疗 (放化组 )。另一组 33例单纯放疗 (单放组 )。放疗采用 6MV或 15MV X线照射 ,中平面DT 5 5～6 5GY ;化疗共 4个周期 ,与放疗同时进行 2个周期 ,放疗结束后 2个周期。结果 随访 3年 ,放化组和单放组近期疗效CR分别为 80 %和 5 1.5 %(P <0 .0 5 )、1、2、3年生存率分别为 74.3%、5 1.4%、34.3%和 48.5 %、30 .3%、2 1.2 %。放化组生存率明显高于单放组 (P <0 .0 5 )。但骨髓抑制及胃肠道反应放化组高于单放组 (P <0 .0 5 )。结论 放化疗同时对食管癌治疗有协同作用 ,值得临床进一步探讨。
Objective To explore the value of concurrent chemoradiotherapy in the treatment of esophageal cancer. Methods Sixty-eight patients with esophageal cancer were randomly divided into two groups. One group of 35 radiotherapy combined with 5 Fu and PDD chemotherapy (radiotherapy group). Another group of 33 cases of radiotherapy alone (radiotherapy group). Radiotherapy with 6MV or 15MV X-ray irradiation, the median plane DT5 5 ~ 6 5GY; chemotherapy a total of 4 cycles, with radiotherapy at the same time for 2 cycles, 2 cycles after radiotherapy. Results The follow-up of 3 years showed that the short-term CR of radiotherapy group and radiotherapy alone group were 80% and 51.5%, respectively (P 0. 05). The 1, 2 and 3-year survival rates were 74.3%, 51.4% and 34.3 % And 48.5%, 30.3%, 2 1.2%. The survival rate of radiotherapy group was significantly higher than that of radiotherapy group (P <0.05). However, the myelosuppression and gastrointestinal reaction radiotherapy group was higher than the single radiotherapy group (P <0.05). Conclusions Radiotherapy and chemotherapy have synergistic effects on the treatment of esophageal cancer at the same time, which is worth further clinical study.